title: Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
abstract: Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the clinic can be translated into the development of predictive in silico models for use in the drug discovery phase. We identified 13 hepatotoxic side effects with high accuracy for classifying marketed drugs for their DILI potential. We then developed in silico predictive models for each of these 13 side effects, which were further combined to construct a DILI prediction system (DILIps). The DILIps yielded 60-70% prediction accuracy for three independent validation sets. To enhance the confidence for identification of drugs that cause severe DILI in humans, the "Rule of Three" was developed in DILIps by using a consensus strategy based on 13 models. This gave high positive predictive value (91%) when applied to an external dataset containing 206 drugs from three independent literature datasets. Using the DILIps, we screened all the drugs in DrugBank and investigated their DILI potential in terms of protein targets and therapeutic categories through network modeling. We demonstrated that two therapeutic categories, anti-infectives for systemic use and musculoskeletal system drugs, were enriched for DILI, which is consistent with current knowledge. We also identified protein targets and pathways that are related to drugs that cause DILI by using pathway analysis and co-occurrence text mining. While marketed drugs were the focus of this study, the DILIps has a potential as an evaluation tool to screen and prioritize new drug candidates or chemicals, such as environmental chemicals, to avoid those that might cause liver toxicity. We expect that the methodology can be also applied to other drug safety endpoints, such as renal or cardiovascular toxicity.
authors.affiliation: Division of Systems Biology, National Center for Toxicological Research, United States Food and Drug Administration, Jefferson, Arizona, USA.
authors.forename: Zhichao
authors.initials: Z
authors.lastname: Liu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Shi
authors.forename: Don
authors.initials: D
authors.lastname: Ding
authors.forename: Reagan
authors.initials: R
authors.lastname: Kelly
authors.forename: Hong
authors.initials: H
authors.lastname: Fang
authors.forename: Weida
authors.initials: W
authors.lastname: Tong
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism*; D016208:Databases, Factual; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008099:Liver / Q000187:drug effects; D008954:Models, Biological; D011237:Predictive Value of Tests
chemical_list: D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents